Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Lilly Aiming at China’s Growing Pharmaceutical Market

publication date: Dec 11, 2009
In an annual review of its business plans, Eli Lilly revealed China’s pharmaceutical market will be a top priority for the company. Lilly has reorganized its corporate structure so that one of its six units would be devoted to emerging markets, and this unit will aim at taking advantage of the expected growth in China. Because one-third of worldwide growth in pharmaceutical markets will come from emerging markets, Lilly decided to recognize the importance of these new markets in its corporate goals. More details...

Stock Symbol: (NYSE LLY)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital